Solid Tumor/Phase I Clinical Trials

Showing 31-38 of 38 items
31.
  • A Study Evaluating the Safety of Escalating Doses of DLYE5953A in Patients With Refractory Solid Tumors
  • This is an open-label, multicenter, Phase I study to evaluate the safety, tolerability, and PK of escalating doses of DLYE5953A administered to patients with incurable, locally advanced, or metastatic solid malignancy that has progressed on standard therapy. The Phase I study consists of two stages: Stage 1 dose-escalation and Stage 2 expansion in selected patients. In Stage 1, a 3 + 3 dose-escalation design will be used to examine the safety, tolerability, and PK of increasing doses of DLYE5953A. In Stage 2, patients will be enrolled to further characterize the safety, tolerability, and PK of the proposed dose and schedule for future studies.
  • Diagnoses: Solid Tumor/Phase I
  • Status: Recruiting
32.
  • Study of MK-3475 in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
  • This study will assess the efficacy and safety of MK-3475 administered to participants with advanced biomarker-positive solid tumors that have not responded to current therapy, for which current therapy is not appropriate, or for which no current therapy exists. The hypothesis is that administration of MK-3475 to participants with some types of solid tumors will result in a clinically meaningful response rate.
  • Diagnoses: Solid Tumor/Phase I
  • Status: Recruiting
33.
  • A Study of GDC-0575 Alone And in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
  • This open-label, multicenter, Phase I, dose-escalation study will evaluate the s afety, tolerability and pharmacokinetics of GDC-0575 administered alone or in co mbination with gemcitabine in patients with refractory solid tumors or lymphoma. In Stage I, cohorts of patients will receive multiple ascending oral doses of G DC-0575 alone (Arm 1) or in combination with intravenous gemcitabine (Arm 2). In Stage II, patients will receive GDC-0575 orally in combination with intravenous gemcitabine at or below the maximum tolerated dose determined in Stage I. Antic ipated time on study treatment is until disease progression or unacceptable toxi city occurs, for a maximum of 17 cycles (approximately 1 year).
  • Diagnoses: Solid Tumor/Phase I
  • Status: Recruiting
34.
35.
  • Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
  • The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced solid tumors, including glioma, that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where cohorts of patients will receive ascending oral doses of AG-120 to determine maximum tolerated dose (MTD) and/or the recommended Phase II dose. The second portion of the study is a dose expansion phase where three cohorts of patients will receive AG-120 to further evaluate the safety, tolerability, and clinical activity of the MTD. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.
  • Diagnoses: Solid Tumor/Phase I
  • Status: Recruiting
36.
37.
38.
Showing 31-38 of 38 items
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms